Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 17/20 | 0.45 |
| ▸ | OXTR | P30559 | 8/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616348 | 0.83 | TSPO (0.39) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL2616338 | 0.83 | TSPO (0.43) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL2628443 | 0.83 | TSPO (0.58) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL2616346 | 0.82 | TSPO (0.38) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL21396930 | 0.78 | TSPO (0.54) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL21378863 | 0.77 | TSPO (0.61) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL5548432 | 0.77 | TSPO (0.56) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL21397115 | 0.76 | TSPO (0.55) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277297 | 0.76 | AVPR1A (0.61) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL30047024 | 0.76 | AVPR1A (0.61) | TSPOAVPR1AOXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | TSPO 1733/4885AVPR1A 1/4885OXTR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.